Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG110 in Fabry Disease
NCT06819514Phase 2Not yet recruiting
- Sponsor
- Hangzhou Jiayin Biotech
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of EXG110 in Fabry disease (FD) (2 arms), sponsored by Hangzhou Jiayin Biotech. Primary endpoints: Safety and tolerability of EXG110 following a single intravenous infusion at 52 weeks, Changes from baseline of kidney function at 6 months and 3 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
EXG110
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06819514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819514.